Abstract: Since its introduction in the People's Republic of China in 1992, minimally invasive esophagectomy (MIE) has shown the classical advantages of minimally invasive surgery over its open counterpart. Like all pioneers of the technique, cardiothoracic surgeons in the People's Republic of China claim that MIE has a lower risk of pulmonary infection, faster recovery, a shorter hospital stay, and a more rapid return to daily activities than open esophagectomy, while offering the same functional and oncologic results. There has been burgeoning interest in MIE in the People's Republic of China since 1995. The last decade has witnessed nationwide growth in the application of MIE and yielded a significant amount of scientific data in support of its clinical merits and advantages. However, no prospective randomized controlled trials have actually investigated the benefits of MIE in the People's Republic of China. Here we review the current data and state of the art MIE treatment for esophageal cancer in the People's Republic of China.
Introduction
The global incidence of esophageal cancer has increased by 50% in the past two decades. 1, 2 Advances in neoadjuvant and adjuvant chemotherapy and chemoradiotherapy have led to increasingly multimodal treatment for patients with esophageal cancer, which has decreased the rate of local recurrence and improved long-term survival for some patients. However, surgical resection with radical lymphadenectomy is regarded as one of the curative options for resectable esophageal cancer. [3] [4] [5] [6] Frequently, due consideration of surgical resection may not be given because of concerns with regard to the morbidity of open esophagectomy.
In an effort to decrease the morbidity associated with open esophagectomy, Chinese surgeons have adopted a minimally invasive approach to esophageal resection. Because of the potential advantages, including avoiding thoracotomy and laparotomy and reducing the rate of pulmonary infections (thus reducing the inpatient stay), 7, 8 minimally invasive esophagectomy (MIE) was introduced into clinical practice in Taiwan 9 in 1992 at the same time as in Western countries, [10] [11] [12] was gradually implemented, and is now a commonplace procedure in the People's Republic of China (Figure 1 ), including in Beijing, [13] [14] [15] Jinan in Shandong Province, 16 Zhengzhou in Henan Province, 17 Nanjing in Jiangsu Province, 18 Shanghai, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Taizhou in Zhejiang Province, [31] [32] [33] Fuzhou in Fujian Province, [34] [35] [36] Taipei  9 and Taichung  37 in Taiwan, Hongkong, [38] [39] [40] Guangzhou in Guangdong Province, 41, 42 Changsha in Hunan Province, 43 Chongqing, 44, 45 and Chengdu [46] [47] [48] 
Operative data on MIE
Key outcomes of the major studies are summarized in the Tables 1 and 2 . Thirty-two relevant papers, consisting of prospective and retrospective studies, were identified. Eight papers directly compared open oesophagectomy and MIE, and 16, 17, 21, 30, 31, 39, 41, 48 five of these involved studies performed prospectively. 16, 31, 39, 41, 48 Common outcome measures included operative data (operative time, blood loss, conversion rate), morbidity (duration of intensive care and total hospital stay), complications (pulmonary complications, anastomotic leaks, chylothorax), mortality data, and follow-up periods. Neoadjuvant treatment numbers were included for each study.
Surgical approaches
Surgical approaches for MIE performed by Chinese cardiothoracic surgeons are multiple and complicated. As listed in Table 1 , the majority of centers use mainly total MIE (laparoscopic and thoracoscopic esophagectomy), whereas hybrid MIE (thoracoscopy and laparotomy/laparoscopy and thoracotomy) is used in routine practice in some centers. At our center, we originally used hybrid MIE 31 but more recently transitioned to a minimally invasive modified McKeown 3-incision total MIE (laparoscopic and thoracoscopic esophagectomy) in 2010. 32, 33 
Figure 2
Numbers of papers related to minimally invasive esophagectomy performed in the People's Republic of China identified in the PubMed/Medline database, using keywords such as "minimally invasive oesophagectomy", "MiE", and "China".
it was first described in Taiwan in 1995 9 and in the People's Republic of China in 1999. 13 The last decade has witnessed nationwide growth in use of MIE, yielding a significant amount of scientific data to support its clinical merits and advantages. Here we review the current data and state of the art for MIE in the treatment of esophageal cancer in the People's Republic of China.
Literature on MIE in the People's Republic of China
The current literature was reviewed by searching the PubMed/ Medline database from January 1992 to December 2012 using keywords such as "minimally invasive oesophagectomy", "MIE", and "China". Sixty-one full articles were found to be relevant to MIE (Figure 2 
Operative time and blood loss
Operative time varied significantly between the studies, reflecting the type of MIE performed as well as accumulated experience and technical skills (Table 1 ). Blood loss also varied significantly from center to center, comprising around 100-700 mL (Table 1) . Major blood loss and need for blood transfusion in particular increased the risk of postoperative morbidity and mortality.
Conversion to open esophagectomy
The conversion rate reported in the literature is in a range of 0%-9.7% (Table 1) oncologic integrity of the procedure should be of supreme importance.
Mortality, morbidity, and postoperative complications
Mortality rates following total MIE vary between 0% and 7.7% ( Median duration of postoperative stay in intensive care following MIE was one day in the majority of studies (Table 2) . MIE is associated with a significant reduction in hospital stay, with a mean postoperative stay of 12 days (Table 2) .
Outcomes
There is little survival data for MIE available in the People's Republic of China. Only one study reported overall survival after MIE. 25 Feng et al reported median survival for patients in a thoracoscope-assisted transthoracic esophagectomy group and in a mediastinoscope-assisted transhiatal esophagectomy group of 34.4 months and 36.8 months, respectively. 25 There do not appear to be any prospective, randomized, controlled trials comparing the oncologic outcome of MIE with that of open esophagectomy. The present knowledge is based mainly on short-term, nonrandomized comparative studies or historical comparisons with outcomes of open surgery. 31, 39, 41, 48 
Conclusion
In conclusion, MIE is becoming more popular in the People's Republic of China now that Chinese cardiothoracic surgeons are receiving adequate training in major centers. Use of the technique is growing in the People's Republic of China, as confirmed by the increasing number of recently published papers on MIE. However, no prospective, randomized, controlled trials have investigated the benefits of MIE in this country. Such trials, directly comparing MIE and open approaches, are urgently needed.
